Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial

Curran, 2016, Keep off the grass? Cannabis, cognition and addiction, Nat Rev Neurosci, 17, 293, 10.1038/nrn.2016.28 Degenhardt, 2018, The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016, Lancet Psychiatry, 5, 987, 10.1016/S2215-0366(18)30337-7 Freeman, 2019, Increasing potency and price of cannabis in Europe, 2006–16, Addiction, 114, 1015, 10.1111/add.14525 Chandra, 2019, New trends in cannabis potency in USA and Europe during the last decade (2008–2017), Eur Arch Psychiatry Clin Neurosci, 269, 5, 10.1007/s00406-019-00983-5 Freeman, 2015, Examining the profile of high-potency cannabis and its association with severity of cannabis dependence, Psychol Med, 45, 3181, 10.1017/S0033291715001178 Meier, 2017, Associations between butane hash oil use and cannabis-related problems, Drug Alcohol Depend, 179, 25, 10.1016/j.drugalcdep.2017.06.015 Freeman, 2018, Changes in cannabis potency and first-time admissions to drug treatment: a 16-year study in the Netherlands, Psychol Med, 48, 2346, 10.1017/S0033291717003877 2019 2018 Di Forti, 2019, The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study, Lancet Psychiatry, 6, 427, 10.1016/S2215-0366(19)30048-3 Nielsen, 2019, Pharmacotherapies for cannabis dependence, Cochrane Database Syst Rev, 12 Bisogno, 2001, Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide, Br J Pharmacol, 134, 845, 10.1038/sj.bjp.0704327 Laprairie, 2015, Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor, Br J Pharmacol, 172, 4790, 10.1111/bph.13250 Freeman, 2019, Medicinal use of cannabis based products and cannabinoids, BMJ, 365 Freeman, 2019, How does cannabidiol (CBD) influence the acute effects of delta-9-tetrahydrocannabinol (THC) in humans? A systematic review, Neurosci Biobehav Rev, 107, 696, 10.1016/j.neubiorev.2019.09.036 Morgan, 2010, Cannabidiol attenuates the appetitive effects of Δ 9-tetrahydrocannabinol in humans smoking their chosen cannabis, Neuropsychopharmacology, 35, 1879, 10.1038/npp.2010.58 Hindocha, 2018, Cannabidiol reverses attentional bias to cigarette cues in a human experimental model of tobacco withdrawal, Addiction, 113, 1696, 10.1111/add.14243 Hurd, 2019, Cannabidiol for the reduction of cue-induced craving and anxiety in drug-abstinent individuals with heroin use disorder: a double-blind randomized placebo-controlled trial, Am J Psychiatry, 176, 911, 10.1176/appi.ajp.2019.18101191 Ren, 2009, Cannabidiol, a nonpsychotropic component of cannabis, inhibits cue-induced heroin seeking and normalizes discrete mesolimbic neuronal disturbances, J Neurosci, 29, 14764, 10.1523/JNEUROSCI.4291-09.2009 Morgan, 2013, Cannabidiol reduces cigarette consumption in tobacco smokers: preliminary findings, Addict Behav, 38, 2433, 10.1016/j.addbeh.2013.03.011 Chesney, 2020, Adverse effects of cannabidiol: a systematic review and meta-analysis of randomized clinical trials, Neuropsychopharmacology, 10.1038/s41386-020-0667-2 Crippa, 2013, Cannabidiol for the treatment of cannabis withdrawal syndrome: a case report, J Clin Pharm Ther, 38, 162, 10.1111/jcpt.12018 Shannon, 2015, Cannabidiol oil for decreasing addictive use of marijuana: a case report, Integr Med (Encinitas), 14, 31 Solowij, 2018, Therapeutic effects of prolonged cannabidiol treatment on psychological symptoms and cognitive function in regular cannabis users: a pragmatic open-label clinical trial, Cannabis Cannabinoid Res, 3, 21, 10.1089/can.2017.0043 Allsop, 2015, Cannabinoid replacement therapy (CRT): nabiximols (sativex) as a novel treatment for cannabis withdrawal, Clin Pharmacol Ther, 97, 571, 10.1002/cpt.109 Lintzeris, 2019, Nabiximols for the treatment of cannabis dependence: a randomized clinical trial, JAMA Intern Med, 179, 1242, 10.1001/jamainternmed.2019.1993 Trigo, 2018, Nabiximols combined with motivational enhancement/cognitive behavioral therapy for the treatment of cannabis dependence: a pilot randomized clinical trial, PLoS One, 13, 10.1371/journal.pone.0190768 Zuardi, 2017, Inverted U-shaped dose-response curve of the anxiolytic effect of cannabidiol during public speaking in real life, Front Pharmacol, 8, 259, 10.3389/fphar.2017.00259 Campos, 2008, Involvement of 5HT1A receptors in the anxiolytic-like effects of cannabidiol injected into the dorsolateral periaqueductal gray of rats, Psychopharmacology (Berl), 199, 223, 10.1007/s00213-008-1168-x Leweke, 2012, Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia, Transl Psychiatry, 2, e94, 10.1038/tp.2012.15 Cunha, 1980, Chronic administration of cannabidiol to healthy volunteers and epileptic patients, Pharmacology, 21, 175, 10.1159/000137430 Kotz, 2013, Predictive validity of the Motivation To Stop Scale (MTSS): a single-item measure of motivation to stop smoking, Drug Alcohol Depend, 128, 15, 10.1016/j.drugalcdep.2012.07.012 Hindocha, 2016, No smoke without tobacco: a global overview of cannabis and tobacco routes of administration and their association with intention to quit, Front Psychiatry, 7, 104, 10.3389/fpsyt.2016.00104 Taylor, 2018, A phase I, randomized, double-blind, placebo-controlled, single ascending dose, multiple dose, and food effect trial of the safety, tolerability and pharmacokinetics of highly purified cannabidiol in healthy subjects, CNS Drugs, 32, 1053, 10.1007/s40263-018-0578-5 Miller, 2012 Gates, 2016, Psychosocial interventions for cannabis use disorder, Cochrane Database Syst Rev, 2016 Curran, 2018, Which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like effects?, Psychol Med, 49, 1574, 10.1017/S003329171800226X Sobell, 1992, Timeline follow-back, 41 Allsop, 2011, The Cannabis Withdrawal Scale development: patterns and predictors of cannabis withdrawal and distress, Drug Alcohol Depend, 119, 123, 10.1016/j.drugalcdep.2011.06.003 Buysse, 1989, The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research, Psychiatry Res, 28, 193, 10.1016/0165-1781(89)90047-4 Beck, 1961, An inventory for measuring depression, Arch Gen Psychiatry, 4, 561, 10.1001/archpsyc.1961.01710120031004 Beck, 1988, An inventory for measuring clinical anxiety: psychometric properties, J Consult Clin Psychol, 56, 893, 10.1037/0022-006X.56.6.893 Berry, 2010